---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-018373"
form_type: "8-K"
ticker: "BBLG"
cik: "0001419554"
company_name: "Bone Biologics Corp"
filed_at: "2023-05-19T23:59:59+00:00"
generated_at: "2026-06-14T19:39:02.041668+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bone Biologics receives Nasdaq delisting notice; plans appeal and reverse stock split

## Summary
- Nasdaq notified BBLG on May 18, 2023 that its common stock and warrants are subject to delisting for failing to maintain $1.00 bid price.
- Company will request a hearing before Nasdaq Hearings Panel to appeal, which stays delisting pending decision.
- Stockholders approved a reverse stock split at ratio between 1:20 and 1:50 on May 1, 2023 to help regain bid price compliance.
- If delisted, company expects securities to trade on OTC Markets platform.

## SEC filing metadata
- accession: 0001493152-23-018373
- form_type: 8-K
- ticker: BBLG
- cik: 0001419554
- company_name: Bone Biologics Corp
- filed_at: 2023-05-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419554/000149315223018373/0001493152-23-018373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419554/000149315223018373/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-018373
- JSON: https://secwatch.observer/filing/0001493152-23-018373.json
- Plain text: https://secwatch.observer/filing/0001493152-23-018373.txt

## Key facts
- Listing & Compliance Notices
  Bone Biologics Corp received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5450(a)(1)
  source text: November 17, 2022, the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that, based upon the closing bid price for the Company’s common stock for the 30 prior consecutive business day period, the Company no longer satisfied the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1), and that it had been provided a 180-calendar day grace period to regain compliance with that requirement, which period expired May 16, 2023. The Company was not eligible to obtain an additional second 180 calendar period to regain compli
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419554/000149315223018373/0001493152-23-018373-index.htm
- Listing & Compliance Notices
  Bone Biologics Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: May 18, 2023, the Company was notified by the Staff that, based upon the Company’s non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) as of May 30, 2023, the Company’s securities, common stock and publically traded warrants, were subject to delisting unless the Company timely appeals the Staff’s determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the issuance of the Panel’s decision followin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419554/000149315223018373/0001493152-23-018373-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.